Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Equity Average (2016 - 2026)

Neurocrine Biosciences filings provide 15 years of Equity Average readings, the most recent being $3.1 billion for Q4 2025.

  • On a quarterly basis, Equity Average rose 17.86% to $3.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 billion, a 17.86% increase, with the full-year FY2025 number at $2.9 billion, up 21.18% from a year prior.
  • Equity Average hit $3.1 billion in Q4 2025 for Neurocrine Biosciences, up from $2.8 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $3.1 billion in Q4 2025 to a low of $1.2 billion in Q1 2021.
  • Median Equity Average over the past 5 years was $1.8 billion (2023), compared with a mean of $2.0 billion.
  • Biggest five-year swings in Equity Average: surged 74.38% in 2021 and later grew 6.84% in 2025.
  • Neurocrine Biosciences' Equity Average stood at $1.4 billion in 2021, then increased by 19.57% to $1.6 billion in 2022, then soared by 30.18% to $2.1 billion in 2023, then grew by 25.38% to $2.7 billion in 2024, then grew by 17.86% to $3.1 billion in 2025.
  • The last three reported values for Equity Average were $3.1 billion (Q4 2025), $2.8 billion (Q3 2025), and $2.6 billion (Q2 2025) per Business Quant data.